Status:
COMPLETED
Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer
Lead Sponsor:
AHS Cancer Control Alberta
Collaborating Sponsors:
Cross Cancer Institute
Conditions:
Lung Neoplasm
Small Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
It is accepted that giving higher doses of chest radiation in as short a time span as possible improves chances of cure. In this study, the investigators propose to give an increased dose of chest rad...
Detailed Description
The ideal chest radiotherapy dose/fractionation scheme for limited stage small cell lung cancer is undefined. Strategies of radiotherapy dose intensification with minimization of overall treatment tim...
Eligibility Criteria
Inclusion
- limited stage small cell lung cancer
- adequate pulmonary function test (FEV1 \>1.0 L, DLCO \>50%)
- signed study consent
- age at least 18 years
- Karnofsky performance status as least 70%
- eligible to receive standard concurrent small cell cancer chemotherapy
Exclusion
- extensive stage disease
- mixed non small cell and small cell histology
- inadequate pulmonary function tests
- not eligible for concurrent chemotherapy
- subtotal or total tumor resection
- previous chest/neck radiotherapy
- prior or concurrent malignancy except non-melanomatous skin unless disease free for last 5 years
- pregnant
- prior chemotherapy for another malignancy
- patients with myocardial infarction within the preceding 6 months of symptomatic heart disease, including, angina, congestive heart failure, uncontrolled arrhythmias
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00907569
Start Date
June 1 2009
End Date
April 1 2011
Last Update
February 22 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2